Dr. Robert Huizinga reports

KANE BIOTECH EXPANDS COMMERCIAL ACTIVITIES IN THE UNITED STATES

Kane Biotech Inc. has signed non-exclusive distribution/sales agreements for its revyve antimicrobial wound gel product line with Patient Care Medical (Austin, Tex.) and Life Biologics (Lakewood, N.J.).

U.S. FDA 510(k) cleared and Health Canada approved revyve antimicrobial wound gel and revyve antimicrobial wound gel spray

These U.S. non-exclusive distribution and sales agreements expand the company's presence in targeted sales channels and geographic markets. Life Biologics distributes nationally in advanced wound care, while Patient Care Medical distributes within Louisiana, Mississippi and the Gulf Coast specializing in in-hospital and mobile wound care facilities. Preparations are under way for initial shipments in the near term.

"Expanding our U.S. distribution network remains a key priority for the company," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "These agreements enhance our access to selected U.S. markets and support our near-term commercialization objectives."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes.

We seek Safe Harbor.